Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-036"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"sv"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-036"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0372
lpv:speaker	lp:Per-Arne Arvidsson2
lpv:spokenAs	member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2002-10-23)3 substitute; Delegation to the European Economic Area Joint Parliamentary Committee (EEA) (2002-03-07--2004-07-19)3 substitute; Committee on Culture, Youth, Education, the Media and Sport (2002-01-17--2004-07-19)3 member; Delegation to the EU-Czech Republic Joint Parliamentary Committee (2002-02-07--2004-04-30)3 member; EPP-ED (1999-07-20--2004-07-19)3 unknown; Moderata samlingspartiet (1999-07-20--2004-07-19)3
lpv:translated text	"Mr President, the effective new medicines have brought about a major revolution in healthcare. They have been a great help to many patients. One example is the modern medicines to combat heart failure, which have not only increased survival rates but have also radically increased the quality of life for sufferers. When, twenty years ago, I was a newly-qualified general practitioner, the information available to me on medicines used to be locked away to prevent unauthorised access. Much has happened since then. Today, everyone with access to the Internet and with sufficient linguistic ability can find out about treatment principles and information on medicines. This trend is good for healthcare as well as being a requirement from patient organisations. The trend certainly places higher demands on doctors, but a doctor will achieve the best relationship with a patient who is well informed. Mr President, trying to block or limit information to patients ties in very poorly with the principles of transparency in modern healthcare. Finally, a comment on Mr Rod and the Group of the Greens/European Free Alliance: Your proposal for double testing of medicines is not just poor but could even be dangerous. Reviews of approved new medicines should not take place after five years, but must be carried out on an ongoing basis."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph